Proactive Investors - Run By Investors For Investors

Imugene will present lead candidate HER-Vaxx at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about the significance of presenting the clinical stage immuno-oncology company's lead candidate - the HER-Vaxx cancer vaccine - at the upcoming American Association for Cancer Research 2019 Annual Meeting.

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

 
View full IMU profile View Profile

Imugene Ltd Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use